Lucid Diagnostics (LUCD) Q4 2024 earnings summary

Executive summary

• Achieved record quarterly test volume in Q4 2024, processing 4,042 EsoGuard tests, up 45% sequentially and 84% year-over-year, with $1.2 million recognized revenue.

• Secured first commercial insurance coverage for EsoGuard, including Highmark Blue Cross Blue Shield of New York and state biomarker legislation agreements.

• NCCN and ACG guidelines now include non-endoscopic biomarker testing, such as EsoGuard, as an alternative to endoscopy, supporting broader adoption.

• Expanded clinical evidence base with new peer-reviewed studies and submitted evidence to MolDX for Medicare LCD reconsideration.

• Strengthened balance sheet through long-term debt refinancing and a $15 million registered direct offering, extending cash runway.

Financial highlights

• Q4 2024 revenue was $1.2 million, up from $1.04 million in Q4 2023 and flat sequentially, with record test volume exceeding 4,000.

• Non-GAAP net loss for Q4 was $10.9 million, or $0.19 per share, consistent with prior quarters.

• GAAP net loss attributable to common stockholders was $11.5 million, or $(0.20) per share, in Q4 2024.

• Cash at year-end was $22.4 million, with pro forma cash of $36.9 million after March financing.

• Quarterly burn rate decreased to $10.1 million, down from a $11 million average in prior quarters.

Outlook and guidance

• Expects revenue growth to accelerate in the second half of 2025 as new sales channels and contractually-guaranteed revenue ramp up.

• Anticipates significant operating leverage and margin improvement with Medicare coverage and increased test volume.

• Optimistic about a positive Medicare MolDX decision in the first half of 2025, enabling broader coverage and faster revenue recognition.